APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs Based on TGF-β1

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs Based on TGF-β1 Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchDrugs Based on TGF-β1 Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs Based on TGF-β1 Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Drugs Based on TGF-β1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs Based on TGF-β1 Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs Based on TGF-β1 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Drugs Based on TGF-β1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs Based on TGF-β1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs Based on TGF-β1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs Based on TGF-β1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs Based on TGF-β1 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs Based on TGF-β1 market include Roche and Shionogi Ltd among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs Based on TGF-β1 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs Based on TGF-β1 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs Based on TGF-β1 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs Based on TGF-β1 market.

Drugs Based on TGF-β1 Segment by Company

Roche

Shionogi Ltd

Drugs Based on TGF-β1 Segment by Type

Pirfenidone

Galunisertib

Others

Drugs Based on TGF-β1 Segment by Application

IPF

Cancer

Others

Drugs Based on TGF-β1 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Drugs Based on TGF-β1 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs Based on TGF-β1 key companies, revenue, market share, and recent developments.

3. To split the Drugs Based on TGF-β1 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs Based on TGF-β1 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs Based on TGF-β1 significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs Based on TGF-β1 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on TGF-β1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on TGF-β1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on TGF-β1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs Based on TGF-β1 industry.

Chapter 3: Detailed analysis of Drugs Based on TGF-β1 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs Based on TGF-β1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs Based on TGF-β1 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs Based on TGF-β1 Industry Trends Table 2. Drugs Based on TGF-β1 Industry Drivers Table 3. Drugs Based on TGF-β1 Industry Opportunities and Challenges Table 4. Drugs Based on TGF-β1 Industry Restraints Table 5. Global Drugs Based on TGF-β1 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs Based on TGF-β1 Revenue Share by Company (2021-2026) Table 7. Global Drugs Based on TGF-β1 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs Based on TGF-β1 Key Company Manufacturing Base & Headquarters Table 9. Global Drugs Based on TGF-β1 Company, Product Type & Application Table 10. Global Drugs Based on TGF-β1 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs Based on TGF-β1 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pirfenidone Table 15. Significant Companies of Galunisertib Table 16. Significant Companies of Others Table 17. Global Drugs Based on TGF-β1 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drugs Based on TGF-β1 Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drugs Based on TGF-β1 Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drugs Based on TGF-β1 Sales Value Share by Type (2021-2026) Table 21. Global Drugs Based on TGF-β1 Sales Value Share by Type (2027-2032) Table 22. Significant Companies of IPF Table 23. Significant Companies of Cancer Table 24. Significant Companies of Others Table 25. Global Drugs Based on TGF-β1 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs Based on TGF-β1 Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drugs Based on TGF-β1 Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drugs Based on TGF-β1 Sales Value Share by Application (2021-2026) Table 29. Global Drugs Based on TGF-β1 Sales Value Share by Application (2027-2032) Table 30. Global Drugs Based on TGF-β1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs Based on TGF-β1 Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drugs Based on TGF-β1 Sales Value Share by Region (2021-2026) Table 33. Global Drugs Based on TGF-β1 Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drugs Based on TGF-β1 Sales Value Share by Region (2027-2032) Table 35. Global Drugs Based on TGF-β1 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs Based on TGF-β1 Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drugs Based on TGF-β1 Sales Value Market Share by Country (2021-2026) Table 38. Global Drugs Based on TGF-β1 Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drugs Based on TGF-β1 Sales Value Market Share by Country (2027-2032) Table 40. Roche Company Information Table 41. Roche Business Overview Table 42. Roche Drugs Based on TGF-β1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Roche Drugs Based on TGF-β1 Product Portfolio Table 44. Roche Recent Development Table 45. Shionogi Ltd Company Information Table 46. Shionogi Ltd Business Overview Table 47. Shionogi Ltd Drugs Based on TGF-β1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Shionogi Ltd Drugs Based on TGF-β1 Product Portfolio Table 49. Shionogi Ltd Recent Development Table 50. Research Programs/Design for This Report Table 51. Authors List of This Report Table 52. Secondary Sources Table 53. Primary Sources List of Figures Figure 1. Drugs Based on TGF-β1 Product Image Figure 2. Global Drugs Based on TGF-β1 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs Based on TGF-β1 Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs Based on TGF-β1 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pirfenidone Image Figure 8. Galunisertib Image Figure 9. Others Image Figure 10. Global Drugs Based on TGF-β1 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs Based on TGF-β1 Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs Based on TGF-β1 Sales Value Share by Type (2021-2032) Figure 13. IPF Image Figure 14. Cancer Image Figure 15. Others Image Figure 16. Global Drugs Based on TGF-β1 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs Based on TGF-β1 Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs Based on TGF-β1 Sales Value Share by Application (2021-2032) Figure 19. Global Drugs Based on TGF-β1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drugs Based on TGF-β1 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drugs Based on TGF-β1 Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drugs Based on TGF-β1 Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drugs Based on TGF-β1 Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drugs Based on TGF-β1 Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drugs Based on TGF-β1 Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drugs Based on TGF-β1 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drugs Based on TGF-β1 Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drugs Based on TGF-β1 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drugs Based on TGF-β1 Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drugs Based on TGF-β1 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Galunisertib
  • Others
Applications
  • IPF
  • Cancer
  • Others
Companies covered
  • Roche
  • Shionogi Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs Based on TGF-β1 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs Based on TGF-β1 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs Based on TGF-β1 Market Dynamics
  1. 2.1 Drugs Based on TGF-β1 Industry Trends
  2. 2.2 Drugs Based on TGF-β1 Industry Drivers
  3. 2.3 Drugs Based on TGF-β1 Industry Opportunities and Challenges
  4. 2.4 Drugs Based on TGF-β1 Industry Restraints
3 Drugs Based on TGF-β1 Market by Company
  1. 3.1 Global Drugs Based on TGF-β1 Company Revenue Ranking in 2025
  2. 3.2 Global Drugs Based on TGF-β1 Revenue by Company (2021-2026)
  3. 3.3 Global Drugs Based on TGF-β1 Company Ranking (2024-2026)
  4. 3.4 Global Drugs Based on TGF-β1 Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs Based on TGF-β1 Company Product Type and Application
  6. 3.6 Global Drugs Based on TGF-β1 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs Based on TGF-β1 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs Based on TGF-β1 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs Based on TGF-β1 Market by Type
  1. 4.1 Drugs Based on TGF-β1 Type Introduction
  2. 4.1.1 Pirfenidone
  3. 4.1.2 Galunisertib
  4. 4.1.3 Others
  5. 4.2 Global Drugs Based on TGF-β1 Sales Value by Type
  6. 4.2.1 Global Drugs Based on TGF-β1 Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs Based on TGF-β1 Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drugs Based on TGF-β1 Sales Value Share by Type (2021-2032)
5 Drugs Based on TGF-β1 Market by Application
  1. 5.1 Drugs Based on TGF-β1 Application Introduction
  2. 5.1.1 IPF
  3. 5.1.2 Cancer
  4. 5.1.3 Others
  5. 5.2 Global Drugs Based on TGF-β1 Sales Value by Application
  6. 5.2.1 Global Drugs Based on TGF-β1 Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs Based on TGF-β1 Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs Based on TGF-β1 Sales Value Share by Application (2021-2032)
6 Drugs Based on TGF-β1 Regional Value Analysis
  1. 6.1 Global Drugs Based on TGF-β1 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs Based on TGF-β1 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs Based on TGF-β1 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs Based on TGF-β1 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs Based on TGF-β1 Sales Value (2021-2032)
  7. 6.3.2 North America Drugs Based on TGF-β1 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs Based on TGF-β1 Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs Based on TGF-β1 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs Based on TGF-β1 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs Based on TGF-β1 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs Based on TGF-β1 Sales Value (2021-2032)
  16. 6.6.2 South America Drugs Based on TGF-β1 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs Based on TGF-β1 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs Based on TGF-β1 Sales Value Share by Country, 2025 VS 2032
7 Drugs Based on TGF-β1 Country-level Value Analysis
  1. 7.1 Global Drugs Based on TGF-β1 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs Based on TGF-β1 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs Based on TGF-β1 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs Based on TGF-β1 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs Based on TGF-β1 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs Based on TGF-β1 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs Based on TGF-β1 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Drugs Based on TGF-β1 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Drugs Based on TGF-β1 Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Shionogi Ltd
  8. 8.2.1 Shionogi Ltd Company Information
  9. 8.2.2 Shionogi Ltd Business Overview
  10. 8.2.3 Shionogi Ltd Drugs Based on TGF-β1 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shionogi Ltd Drugs Based on TGF-β1 Product Portfolio
  12. 8.2.5 Shionogi Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst